- Home
- VYGR vs EDF Comparison
VYGR vs EDF Comparison
Compare VYGR & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- EDF
- Stock Information
- Founded
- VYGR 2013
- EDF 2010
- Country
- VYGR United States
- EDF United States
- Employees
- VYGR N/A
- EDF N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- EDF Investment Managers
- Sector
- VYGR Health Care
- EDF Finance
- Exchange
- VYGR Nasdaq
- EDF Nasdaq
- Market Cap
- VYGR 172.6M
- EDF 156.6M
- IPO Year
- VYGR 2015
- EDF N/A
- Fundamental
- Price
- VYGR $3.19
- EDF $5.07
- Analyst Decision
- VYGR Strong Buy
- EDF
- Analyst Count
- VYGR 8
- EDF 0
- Target Price
- VYGR $14.33
- EDF N/A
- AVG Volume (30 Days)
- VYGR 647.7K
- EDF 160.6K
- Earning Date
- VYGR 08-12-2025
- EDF 01-01-0001
- Dividend Yield
- VYGR N/A
- EDF 13.14%
- EPS Growth
- VYGR N/A
- EDF N/A
- EPS
- VYGR N/A
- EDF N/A
- Revenue
- VYGR $66,958,000.00
- EDF N/A
- Revenue This Year
- VYGR N/A
- EDF N/A
- Revenue Next Year
- VYGR $78.89
- EDF N/A
- P/E Ratio
- VYGR N/A
- EDF N/A
- Revenue Growth
- VYGR N/A
- EDF N/A
- 52 Week Low
- VYGR $2.65
- EDF $3.51
- 52 Week High
- VYGR $9.55
- EDF $5.50
- Technical
- Relative Strength Index (RSI)
- VYGR 48.20
- EDF 54.51
- Support Level
- VYGR $3.15
- EDF $5.00
- Resistance Level
- VYGR $3.79
- EDF $5.09
- Average True Range (ATR)
- VYGR 0.21
- EDF 0.07
- MACD
- VYGR 0.00
- EDF 0.00
- Stochastic Oscillator
- VYGR 16.67
- EDF 84.21
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.